1
|
Bassi PU, Osakwe AI, Suku C, Kalat M, Elagbaje C, Isah A, Ayinbuomwan S, Wammanda RD, Bob-Okon II, Ambe J, Mava Y, Adesina AO, Ugochukwu CG, Nyong EE, Ogunleye OO, Onuoha F, Jalo I, Adegoke VO, Balogun ST, Ntadom G, Ejiekpe FN, Tahir R, Dabit K, Amodu AA, Nwaosu S, Habib AT. Cohort event monitoring of patients treated for uncomplicated malaria with artemisinin-based combination therapies in selected hospitals and community pharmacies in Nigeria. Niger Postgrad Med J 2016; 23:172-181. [PMID: 28000637 DOI: 10.4103/1117-1936.196246] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
AIMS AND OBJECTIVES The study was designed with the broad objective of determining the safety profile of artemisinin-based combination therapies amongst Nigerian population. PATIENTS AND METHODS This was a cohort event monitoring (CEM) programme involving monitoring adverse events (AEs) in malaria patients treated with either artemether-lumefantrine (AL) or artesunate-amodiaquine (AA) in healthcare facilities in Nigeria. The study involved continuous enrolment of patients with malaria and treated with either AL or AA at the various sites until a total cohort of 600 patients were enrolled at each site. Patients were monitored from the onset of therapy, and on days 3 and 7 from the first day of treatment to identify AEs that may occur. RESULTS A total of 6102 AEs were recorded in 10,259 patients monitored during the programme. Of 4896 patients who received AA, 4233 (86.5%) patients reported at least one AE while 1869 (34.8%) AEs out of 5363 patients who received AL were reported (P = 0.010). The predominant incidence of each specific AE reported in each group among the patients who received AA and AL includes body weakness 30.8%/7.5%, dizziness 10.3%/3.9%, restlessness 5.02/1.12%, vomiting 3.5/1.03% and drowsiness 3.1/1.5% for AA and AL, respectively. There were more AEs among patients with co-morbid conditions and patients in the younger age groups (9-<15 years), P = 0.000. CONCLUSIONS Various types of AEs were seen and documented during the CEM programme. The findings suggested that the AA/AL monitored during this programme was generally safe and remarkably well tolerated among the Nigerian populations.
Collapse
Affiliation(s)
- P U Bassi
- Department of Pharmacology and Therapeutics, College of Health Sciences, University of Abuja, Abuja, Nigeria
| | - A I Osakwe
- National Agency for Food and Drug Administration and Control, Abuja, Nigeria
| | - C Suku
- National Agency for Food and Drug Administration and Control, Abuja, Nigeria
| | - M Kalat
- National Agency for Food and Drug Administration and Control, Abuja, Nigeria
| | - C Elagbaje
- National Agency for Food and Drug Administration and Control, Abuja, Nigeria
| | - A Isah
- Department of Medicine, Clinical Pharmacology Unit, University of Benin Teaching Hospital, Benin City, Nigeria
| | - S Ayinbuomwan
- Department of Medicine, Clinical Pharmacology Unit, University of Benin Teaching Hospital, Benin City, Nigeria
| | - R D Wammanda
- Department of Paediatrics, Ahmadu Bello University Teaching Hospital, Zaria, Nigeria
| | - I I Bob-Okon
- Department of Paediatrics, Federal Medical Centre, Yenagoa, Nigeria
| | - J Ambe
- Department of Paediatrics, University of Maiduguri Teaching Hospital, Maiduguri, Nigeria
| | - Y Mava
- Department of Paediatrics, University of Maiduguri Teaching Hospital, Maiduguri, Nigeria
| | - A O Adesina
- Department of Obstetrics and Gynecology, University College Hospital, Ibadan, Nigeria
| | - C G Ugochukwu
- Department of Paediatrics, Nnamdi Azikiwe University Teaching Hospital, Nnewi, Nigeria
| | - E E Nyong
- Department of Paediatrics, University of Uyo Teaching Hospital, Akwa Ibom, Nigeria
| | - O O Ogunleye
- Lagos State University Teaching Hospital, Lagos, Nigeria
| | - F Onuoha
- Federal Medical Centre, Owerri, Nigeria
| | - I Jalo
- Department of Paediatrics, Federal Teaching Hospital, Gombe, Nigeria
| | - V O Adegoke
- NIPRD Research Clinic, National Institute for Pharmaceutical Research and Development, Abuja, Nigeria
| | - S T Balogun
- Department of Clinical Pharmacology and Therapeutics, University of Maiduguri, Maiduguri, Nigeria
| | - G Ntadom
- National Malaria Control Programme, FMoH, Abuja, Nigeria
| | | | - R Tahir
- Rata Pharmacy, Maiduguri, Nigeria
| | - K Dabit
- Skylark Pharmacy, Abuja, Nigeria
| | - A A Amodu
- Federal Medical Center, Makurdi, Nigeria
| | - S Nwaosu
- Department of Mathematics, Federal University of Technology, Makurdi, Nigeria
| | - A T Habib
- Waziri Shehu Specialist Hospital, Kano, Nigeria
| |
Collapse
|